Maimonides Minocycline in Stroke Study

Description

The goal of this study is to determine if oral Minocycline's proposed neuroprotective effects further improve the clinical outcomes, including mortality, of acute stroke patients beyond the current standard stroke care in a large scale randomized prospective open label (outcome assessor blinded) clinical trial. Participants will be randomly assigned (1:1) to take Minocycline 200mg orally every 24 hours for five days, starting within 24 hours from stroke symptoms onset, in addition to standard care or standard care alone. NIHSS (The National Institutes of Health Stroke Scale) and mRS (Modified Rankin Scale) will be collected at the time of presentation, discharge and again at 30- and 90-days post-discharge. All-cause mortality will also be obtained at 30 days and 90 days.

Conditions

Stroke, Acute, Ischemic Stroke, Hemorrhagic Stroke, Mortality, Morbidity

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this study is to determine if oral Minocycline's proposed neuroprotective effects further improve the clinical outcomes, including mortality, of acute stroke patients beyond the current standard stroke care in a large scale randomized prospective open label (outcome assessor blinded) clinical trial. Participants will be randomly assigned (1:1) to take Minocycline 200mg orally every 24 hours for five days, starting within 24 hours from stroke symptoms onset, in addition to standard care or standard care alone. NIHSS (The National Institutes of Health Stroke Scale) and mRS (Modified Rankin Scale) will be collected at the time of presentation, discharge and again at 30- and 90-days post-discharge. All-cause mortality will also be obtained at 30 days and 90 days.

Effect of Oral Minocycline on Acute Stroke Outcome: A Randomized Open Label Prospective Study

Maimonides Minocycline in Stroke Study

Condition
Stroke, Acute
Intervention / Treatment

-

Contacts and Locations

Brooklyn

Maimonides Medical Center, Brooklyn, New York, United States, 11219

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age \>/=18
  • 2. Acute onset neurological deficit consistent with acute ischemic stroke or on imaging consistent with acute ischemia as defined by WHO (World Health Organization) guidelines
  • 3. Acute onset of neurological deficits with intracerebral Hemorrhage on imaging consistent with intracerebral bleed
  • 4. The onset of symptoms less than 24 hours
  • 5. Measurable neurological deficit using NIHSS (National Institutes of Health Stroke Scale )
  • 1. Clinically not suspect stroke.
  • 2. Allergic to the Tetracycline group of medications or Intolerance to Minocycline
  • 3. Pregnancy or suspected pregnancy
  • 4. Previous history of intolerance to minocycline
  • 5. Acute or chronic renal failure
  • 6. Any patients with contraindications to undergo CT/ MRI
  • 7. Life expectancy less than one year or severe co-morbidities or comfort measure only (CMO) on admission
  • 8. Pre-existing infectious disease requiring antibiotics
  • 9. Inability to tolerate enteral medications/feeds
  • 10. Patient/ family refusal

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Maimonides Medical Center,

Study Record Dates

2026-02-01